{
    "ticker": "AQST",
    "name": "Aquestive Therapeutics, Inc.",
    "description": "Aquestive Therapeutics, Inc. is a pharmaceutical company dedicated to developing and commercializing innovative medicines that address unmet medical needs. Founded in 2012 and headquartered in Warren, New Jersey, Aquestive leverages its proprietary drug delivery technologies to create oral formulations of complex compounds, enhancing the efficacy and convenience of treatments for patients. The company's lead product, Kynmobi, is a sublingual film formulation of apomorphine, approved for the treatment of 'off' episodes in patients with Parkinson's disease. This innovative approach allows for rapid absorption of medication, providing patients with timely relief from their symptoms. Additionally, Aquestive is engaged in the development of other products that aim to improve the treatment of various neurological and psychiatric conditions, including epilepsy and schizophrenia. The company is committed to advancing its pipeline through strategic partnerships and collaborations, ensuring that it remains at the forefront of pharmaceutical innovation. This focus on patient-centric solutions is driven by a mission to improve the quality of life for individuals suffering from debilitating conditions through accessible and effective therapies.",
    "industry": [
        "Pharmaceuticals",
        "Biotechnology"
    ],
    "headquarters": "Warren, New Jersey, USA",
    "founded": "2012",
    "website": "https://www.aquestive.com",
    "ceo": "Daniel J. Calvo",
    "social_media": {
        "twitter": "https://twitter.com/Aquestive",
        "linkedin": "https://www.linkedin.com/company/aquestive-therapeutics/"
    },
    "investor_relations": "https://investors.aquestive.com",
    "key_executives": [
        {
            "name": "Daniel J. Calvo",
            "position": "CEO"
        },
        {
            "name": "Kurt L. W. R. F. A. K. H. McEwen",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Prescription Medicines",
            "products": [
                "Kynmobi"
            ]
        }
    ],
    "seo": {
        "meta_title": "Aquestive Therapeutics, Inc. | Innovative Pharmaceutical Solutions",
        "meta_description": "Learn about Aquestive Therapeutics, Inc., a pioneer in innovative drug delivery systems and prescription medicines that improve patient outcomes.",
        "keywords": [
            "Aquestive",
            "Pharmaceuticals",
            "Drug Delivery",
            "Kynmobi",
            "Parkinson's Disease",
            "Innovative Medicines"
        ]
    },
    "faq": [
        {
            "question": "What is Aquestive known for?",
            "answer": "Aquestive is known for its innovative drug delivery technologies and its lead product, Kynmobi, for treating Parkinson's disease."
        },
        {
            "question": "Who is the CEO of Aquestive?",
            "answer": "Daniel J. Calvo is the CEO of Aquestive Therapeutics, Inc."
        },
        {
            "question": "Where is Aquestive headquartered?",
            "answer": "Aquestive is headquartered in Warren, New Jersey, USA."
        },
        {
            "question": "What are the main products of Aquestive?",
            "answer": "The main product of Aquestive is Kynmobi, a sublingual film for Parkinson's disease."
        },
        {
            "question": "When was Aquestive founded?",
            "answer": "Aquestive was founded in 2012."
        }
    ],
    "competitors": [
        "VRTX",
        "AMGN",
        "INCY",
        "SNY"
    ],
    "related_stocks": [
        "GILD",
        "BMY",
        "JNJ",
        "PFE"
    ]
}